Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature
BLM, being an off-the-shelf therapy, with acceptable toxicity even in frail patients, may be a valuable option in AL, with a high ORR, and a signal for durable responses and high-quality organ responses.
Authors
- Moshe E. Gatt (ORCID: https://orcid.org/0000-0002-9426-4482)
- Noa Lavi (ORCID: https://orcid.org/0000-0002-2511-8940)
- Eyal Lebel (ORCID: https://orcid.org/0000-0001-5215-7278)
- Hila Magen (ORCID: https://orcid.org/0000-0002-3990-394X)
- Miri Assayag (ORCID: https://orcid.org/0000-0001-6698-5349)
- Vladimir Vainstein (ORCID: https://orcid.org/0000-0002-4412-4094)
- Tamir Shragai (ORCID: https://orcid.org/0000-0002-3741-689X)
- Irit Avivi (ORCID: https://orcid.org/0000-0001-8663-444X)
- Giovanni O. Palladini (ORCID: https://orcid.org/0000-0001-5994-5138)
- P. Milani (ORCID: https://orcid.org/0000-0002-8799-3070)
Institutions
- Tel Aviv University (IL)
- Hebrew University of Jerusalem (IL)
- University of Pavia (IT)
- Tel Aviv Sourasky Medical Center (IL)
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Rambam Health Care Campus (IL)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1159/000541594
- Citations
- 6
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.40